Compare GE HealthCare Technologies Inc. Common Stock (GEHC) vs Verisign, Inc. (VRSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE HealthCare Technologies Inc. Common Stock vs Verisign, Inc. — how do they compare? GE HealthCare Technologies Inc. Common Stock trades at $68.66 (market cap $31.07B), while Verisign, Inc. trades at $302.38 (market cap $27.28B). The key difference: GE HealthCare Technologies Inc. Common Stock and Verisign, Inc. are close in size by market cap, and Verisign, Inc. pays the higher dividend (1.07%). Which is the better fit depends on your goals.
| GEHC | VRSN | |
|---|---|---|
Market Cap | $31.07B | $27.28B |
Volume | 3,443,020 | 695,583 |
Sector | Health | Technology |
52-Week High | $88.16 | $310.00 |
52-Week Low | $59.48 | $211.49 |
Enterprise Value | $39.53B | $28.59B |
Dividend Yield | 0.23% | 1.07% |
Typical Hold Time | — | 124 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
VeriSign (VRSN) trades at $301.41, down 0.43% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $348. The stock shows strong profitability with a net income margin near 50% and consistent revenue growth, though recent quarterly EPS results have been mixed. Key developments include an upcoming Q3 2026 earnings report and ongoing institutional accumulation, balanced by an antitrust lawsuit and insider selling activity.
The outlook for VRSN remains positive given its dominant market position and high margins, with potential upside to analyst targets. Risks include legal challenges, competitive pressures, and valuation multiples above industry averages. Earnings performance and resolution of regulatory issues will be critical near-term catalysts for the stock.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About GE HealthCare Technologies Inc. Common Stock
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
